Aimei Health Technology Co. Ltd. shares fell 30% on July 9, 2026, following the termination of its proposed merger agreement with special purpose acquisition company United Hydrogen Group Inc. The termination was announced by the companies, effectively canceling the planned business combination that would have taken Aimei Health public. The sharp decline erased approximately $45 million in market capitalization from the Chinese telehealth services provider.
Context — [why this matters now]
The termination reflects a continued cooling in the SPAC market after its peak activity in 2021. Investor appetite for de-SPAC transactions has diminished significantly amid heightened regulatory scrutiny and poor post-merger performance of many completed deals. The last major SPAC merger termination occurred on April 3, 2026, when a biotech-focused blank check company canceled its $850 million combination, triggering a 27% decline in the target's private valuation.
The current macro environment compounds challenges for pre-revenue companies seeking public listings. The 10-year Treasury yield sits at 4.31%, creating competitive returns that pressure growth stock valuations. The Federal Reserve's higher-for-longer stance has particularly damaged investor enthusiasm for speculative healthcare and technology ventures needing future capital raises.
The deal collapse originated from failure to satisfy closing conditions by the agreement's outside date. Neither party will pay termination fees, indicating mutual recognition that market conditions rendered the transaction untenable. United Hydrogen raised $200 million in its March 2025 IPO specifically to identify a merger target in the clean energy sector.
Data — [what the numbers show]
Aimei Health shares closed at $3.15, down $1.35 from the previous session's $4.50 closing price. Trading volume surged to 8.4 million shares, nearly 15 times the 90-day average volume of 560,000 shares. The decline represented the largest single-day drop since the company's own SPAC merger in September 2024.
The terminated agreement valued Aimei Health at approximately $600 million, representing a 12.7x multiple on the company's projected 2027 revenue of $47.2 million. By comparison, publicly traded telehealth peer Teladoc Health trades at 2.8x forward revenue amid ongoing sector-wide profitability challenges.
United Hydrogen shares remained unchanged at $10.05, their NAV floor price, with minimal trading volume. The SPAC has until September 2026 to complete an alternative merger before facing liquidation. Only 14% of SPACs IPOd in 2025 have successfully completed mergers, down from 78% in 2021.
Analysis — [what it means for markets / sectors / tickers]
The failed merger signals continued risk aversion toward pre-profit healthcare services companies. Public market investors increasingly demand clear paths to profitability rather than growth-at-all-costs narratives. This sentiment negatively affects other pending healthcare SPAC deals including MedTech Acquisition Corp's proposed combination with surgical robotics firm Precision Inc.
United Hydrogen's focus on the hydrogen energy sector now turns to finding an alternative target, though time constraints create negotiation disadvantages. The failed deal may benefit competing hydrogen infrastructure companies like Plug Power and FuelCell Energy by reducing future equity dilution from a new publicly traded competitor.
Short interest in Aimei Health reached 18% of float prior to the announcement, suggesting sophisticated investors anticipated deal completion risks. The termination validates bearishtheses on Chinese companies accessing US capital markets through SPAC structures following increased SEC scrutiny of offshore variable interest entities.
Outlook — [what to watch next]
United Hydrogen must identify a new merger target before its September 2026 deadline to avoid liquidation. The SPAC's focus on hydrogen energy infrastructure suggests potential targets like private electrolyzer manufacturers or fuel cell technology developers. Any new announcement will require shareholder approval and regulatory clearance.
Aimei Health faces diminished prospects for near-term public market access following the deal collapse. The company may seek private funding at a discounted valuation or pursue a traditional IPO after demonstrating several quarters of profitability. Chinese regulatory approval for overseas listings remains another variable.
Key levels to watch include Aimei Health's book value of $2.85 per share, which may provide technical support. Resistance likely forms at the $3.80 level where the stock traded prior to merger announcement rumors. The Defiance Next Gen SPAC Derived ETF (SPAK) holds positions in both companies and may experience outflows.
Frequently Asked Questions
What happens to United Hydrogen after the merger termination?
United Hydrogen will continue searching for a suitable merger target until its September 2026 deadline. The SPAC holds approximately $195 million in trust after accounting for underwriter fees and operational expenses. If no merger is completed, the company will liquidate and return $10.05 per share to investors plus accrued interest.
How does this affect other Chinese companies seeking US listings?
The failed deal reinforces investor skepticism toward Chinese companies accessing US markets through SPAC mergers. Regulatory concerns about variable interest entity structures and auditing compliance continue creating obstacles. Traditional IPOs face similar challenges, potentially pushing more Chinese companies toward Hong Kong or domestic listings.
What are the tax implications for Aimei Health shareholders?
Shareholders who purchased above the current price realize capital losses for tax purposes. The termination itself doesn't create taxable events unless investors sold shares during the decline. Wash sale rules apply if investors repurchase shares within 30 days of selling at a loss.
Bottom Line
Aimei Health's failed SPAC merger reflects capital market rejection of speculative growth stories lacking near-term profitability.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
